Table 2.
Summary of the Immunogenicity Data (Mean Geometric Mean Concentration [GMC] and Seroconversion) for Rotarix by World Bank Income Group
| Income group | No. of countries | GMC 1–2 months after second dose,a U/mL
|
Seroconversion,b %
|
||
|---|---|---|---|---|---|
| Mean | Difference from high-income group (95% CI) | Mean | Difference from high-income group (95% CI) | ||
| High | 9 | 205.6 | … | 86 | … |
|
| |||||
| Upper-middle | 6 | 106.6 | −99.1 (−195.0 to −3.0) | 72 | −14 (−29 to 1) |
|
| |||||
| Lower-middle | 6 | 90.5 | −115.1 (−224.0 to −5.9) | 75 | −11 (−27 to 6) |
|
| |||||
| Low | 3 | 67.3 | −138.3 (−276.4 to −1.0) | 63 | −23 (−44 to −2) |
NOTE. Data were obtained from GlaxoSmithKline [7]. CI, confidence interval.
a
Serum rotavirus IgA antibody concentrations 1–2 months after dose 2.
b
Defined as a GMC >20 U/mL.